Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025
27/05/2025 13:51
May 27 (Reuters) - Theriva Biologics Inc TOVX.A: THERIVA™ BIOLOGICS ANNOUNCES PRESENTATION OF DATA FROM VCN-01 RETINOBLASTOMA PHASE 1 CLINICAL TRIAL AT ASCO 2025 AND INVESTIGATOR MEETING TO REVIEW TOPLINE DATA FROM THE VIRAGE PHASE 2B TRIAL OF VCN-01 IN METASTATIC PANCREATIC CANCER Source text: ID:nGNX44PHBd Further company coverage: TOVX.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theriva Biologics
See all newsTheriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025